What is CLDN18.2?
CLDN18.2 is a biomarker that can be assessed in tumor tissue. A specialist reviews the pathology, testing method, and results together with the patient's diagnosis and treatment history.
Patient information · Gastric cancer
CLDN18.2 CAR-T: preparing for a specialist discussion
Learn which records may be useful when discussing satri-cel (CT041) with a qualified oncology team in China.
What approval has been announced?
On 22 June 2026, CARsgen announced Chinese approval of satricabtagene autoleucel (satri-cel/CT041), described as the world's first approved CAR-T product for solid tumors. The announced indication is CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after failure of at least two prior treatment lines.
What should you prepare?
Available pathology and IHC reports, CLDN18.2 and HER2 results, recent imaging, a dated treatment history, blood tests, current medicines, and a summary of the patient's current condition. The receiving team confirms any additional testing and safety assessment.
Source announcement: 22 June 2026Read the CARsgen approval announcement
This is general information, not an assessment of treatment suitability. H&C Care coordinates records and communication. Receiving clinicians must confirm the current approved label, eligibility, risks, availability, and costs for the individual patient; access and outcomes are not guaranteed.
Start an enquiryHere for your next step
Let's start with a conversation
Tell us where you are and what support your family needs. We will discuss the appropriate records and contact channel with you before you send a full medical file.
New patient enquiriesinfo@hccareadvisory.com
Service coordinationcontact@hccareadvisory.com
Existing patient supportsupport@hccareadvisory.com
+852 9581 3961Please do not send passport copies or a full medical file in your first message. Contact local emergency services for urgent medical help.